111 related articles for article (PubMed ID: 22019627)
1. Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: association with CD34(+) mobilization and with disease-free survival.
Milone G; Avola G; Leotta S; Strano A; Camuglia MG; Pinto V; Mercurio S; Poidomani M; Coppoletta S; Di Marco AL; Consoli C; Triolo A; Spadaro A; Privitera A; Ragusa A; Tibullo D; Di Mercurio S
Exp Hematol; 2012 Jan; 40(1):35-47.e2. PubMed ID: 22019627
[TBL] [Abstract][Full Text] [Related]
2. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
3. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial.
Keating S; Suciu S; de Witte T; Zittoun R; Mandelli F; Belhabri A; Amadori S; Fibbe W; Gallo E; Fillet G; Varet B; Meloni G; Hagemeijer A; Fazi P; Solbu G; Willemze R; ;
Leukemia; 2003 Jan; 17(1):60-7. PubMed ID: 12529661
[TBL] [Abstract][Full Text] [Related]
4. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
5. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
Carlo-Stella C; Tabilio A; Regazzi E; Garau D; La Tagliata R; Trasarti S; Andrizzi C; Vignetti M; Meloni G
Bone Marrow Transplant; 1997 Sep; 20(6):465-71. PubMed ID: 9313879
[TBL] [Abstract][Full Text] [Related]
6. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
8. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
10. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
12. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
Novitzky N; Mohamed R
Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
[TBL] [Abstract][Full Text] [Related]
13. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
14. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.
Milone G; Poidomani M; Leotta S; Avola G; Camuglia MG; Privitera A; Consoli C; Mercurio S; Romeo MA; Di Marco A; Di Mercurio S; Spadaro A; Palumbo GA; Tedeschi P
Bone Marrow Transplant; 2012 Jan; 47(1):24-32. PubMed ID: 21399670
[TBL] [Abstract][Full Text] [Related]
16. Phenotyping of acute myelocytic leukemia (AML) progenitors: an approach for tracing minimal numbers of AML cells among normal bone marrow.
Delwel R; van Gurp R; Bot F; Touw I; Löwenberg B
Leukemia; 1988 Dec; 2(12):814-9. PubMed ID: 3199876
[TBL] [Abstract][Full Text] [Related]
17. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
19. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
20. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome.
Feller N; Schuurhuis GJ; van der Pol MA; Westra G; Weijers GW; van Stijn A; Huijgens PC; Ossenkoppele GJ
Leukemia; 2003 Jan; 17(1):68-75. PubMed ID: 12529662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
